Akero Therapeutics develops medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. Akero's lead clinical program, AKR-001, is a long-acting Fc fusion modified FGF21 protein and potential treatment for NASH. AKR-001 builds upon two decades of work on FGF21 biology. It is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.